[go: up one dir, main page]

WO2005080418A3 - Multimerised hiv fusion inhibitors - Google Patents

Multimerised hiv fusion inhibitors Download PDF

Info

Publication number
WO2005080418A3
WO2005080418A3 PCT/DK2005/000121 DK2005000121W WO2005080418A3 WO 2005080418 A3 WO2005080418 A3 WO 2005080418A3 DK 2005000121 W DK2005000121 W DK 2005000121W WO 2005080418 A3 WO2005080418 A3 WO 2005080418A3
Authority
WO
WIPO (PCT)
Prior art keywords
multimerised
fusion proteins
fusion inhibitors
hiv fusion
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2005/000121
Other languages
French (fr)
Other versions
WO2005080418A2 (en
Inventor
Michael Etzerodt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Bio Denmark AS
Original Assignee
Roche Bio Denmark AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Bio Denmark AS filed Critical Roche Bio Denmark AS
Priority to US11/064,115 priority Critical patent/US20050202043A1/en
Priority to EP05706783A priority patent/EP1720899A2/en
Priority to BRPI0507949-7A priority patent/BRPI0507949A/en
Publication of WO2005080418A2 publication Critical patent/WO2005080418A2/en
Publication of WO2005080418A3 publication Critical patent/WO2005080418A3/en
Anticipated expiration legal-status Critical
Priority to US12/015,493 priority patent/US20100048879A1/en
Priority to US12/420,680 priority patent/US20100028995A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

There are provided multimeric fusion proteins exhibiting anti-viral activity. The fusion proteins comprise the HR2 region of the ectodomain of the human immunodeficiency virus gp41 protein which is fused to a multimerisation domain peptide such as a trimerisation domain derived from tetranectin. The multimerised fusion proteins may be used as HIV fusion inhibitors in the treatment of AIDS.
PCT/DK2005/000121 2004-02-23 2005-02-23 Multimerised hiv fusion inhibitors Ceased WO2005080418A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US11/064,115 US20050202043A1 (en) 2004-02-23 2005-02-23 Multimerised HIV fusion inhibitors
EP05706783A EP1720899A2 (en) 2004-02-23 2005-02-23 Multimerised hiv fusion inhibitors
BRPI0507949-7A BRPI0507949A (en) 2004-02-23 2005-02-23 multimerized hiv fusion inhibitors
US12/015,493 US20100048879A1 (en) 2004-02-23 2008-01-16 Multimerised hiv fusion inhibitors
US12/420,680 US20100028995A1 (en) 2004-02-23 2009-04-08 Tetranectin Trimerizing Polypeptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54620004P 2004-02-23 2004-02-23
DKPA200400283 2004-02-23
US60/546,200 2004-02-23
DKPA200400283 2004-02-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/064,115 Continuation US20050202043A1 (en) 2004-02-23 2005-02-23 Multimerised HIV fusion inhibitors

Publications (2)

Publication Number Publication Date
WO2005080418A2 WO2005080418A2 (en) 2005-09-01
WO2005080418A3 true WO2005080418A3 (en) 2005-09-22

Family

ID=34888853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000121 Ceased WO2005080418A2 (en) 2004-02-23 2005-02-23 Multimerised hiv fusion inhibitors

Country Status (3)

Country Link
EP (1) EP1720899A2 (en)
BR (1) BRPI0507949A (en)
WO (1) WO2005080418A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143276A1 (en) * 2007-10-08 2009-06-04 Anaphore, Inc. Trimeric IL-1Ra
GB0422439D0 (en) * 2004-10-08 2004-11-10 European Molecular Biology Lab Embl Inhibitors of infection
CN1793170A (en) * 2005-12-14 2006-06-28 中国人民解放军军事医学科学院生物工程研究所 Polypeptide of inhibiting HIV virus fusion and application thereof
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
EP2117576B1 (en) * 2007-02-08 2014-04-16 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
CN101889022A (en) * 2007-10-08 2010-11-17 阿纳福公司 Trimeric IL-1Ra
EP2799448A1 (en) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
CA2868735C (en) 2011-03-28 2020-02-25 University Of Utah Research Foundation D-peptide conjugates comprising a membrane localizing potency-enhancing cargo molecule for inhibiting hiv entry
US10487121B2 (en) 2016-01-07 2019-11-26 Navigen, Inc. D-peptide inhibitors of HIV entry and methods of use
WO2023039242A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Multivalent interferon particles compositions and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013165A1 (en) * 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Pegylated t1249 polypeptide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013165A1 (en) * 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Pegylated t1249 polypeptide

Also Published As

Publication number Publication date
BRPI0507949A (en) 2007-07-24
EP1720899A2 (en) 2006-11-15
WO2005080418A2 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
WO2020252393A8 (en) Compositions and methods for the treatment of human immunodeficiency virus
WO2008118849A3 (en) Hiv-1 protease inhibitors
WO2005080418A3 (en) Multimerised hiv fusion inhibitors
EA200801798A1 (en) VIROSOMOPROGABLE VESICULAS CONTAINING ANTIGENS DERIVED FROM GP41
WO2012012352A3 (en) Modified peptides and proteins
NZ598834A (en) Prevention, treatment and diagnosis of P. gingivalis infection
CL2004000648A1 (en) AYB CRYSTALLINE PHASE OF CYCLOPROPA ACID [E] PIRROLO [1,2, a] DIAZACICLOPENTADECINO-14a (5H) -CARBOXILICO-6 - [[[(CICLOPENTILOXI) CARBONIL] AMINO] -1,2,3,6,7,8, 9,10,11,13a, 14,15,16,16a-TETRADECAHYDRO-2 - [[7-METOXI-2- [2 - [(1-METHYL) AMINO] -4-TIAZOLIL] -4-QUINOLIN
WO2008103380A3 (en) Hepatitis b virus compositions and methods of use
WO2010022740A3 (en) Hiv-1 envelope polypeptides for hiv vaccine
WO2009099777A3 (en) Chimeric hiv fusion proteins as vaccines
AR029810A1 (en) METHODS AND COMPOSITIONS FOR THE INHIBITION OF THE EVENTS ASSOCIATED WITH THE MEMBRANE FUSION, INCLUDING THE RSV TRANSMISSION
IL178205A0 (en) Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
WO2010041241A3 (en) Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
Hollier et al. The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function
WO2010091373A3 (en) Trimerich hiv fusion inhibitors for treating or preventing hiv infection
WO2005002501A3 (en) Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
WO2004029201A3 (en) Peptide derivative fusion inhibitors of hiv infection
WO2008064072A3 (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
WO2004070002A3 (en) Cell lines and host nucleic acid sequences related to infectious disease
WO2006077601A3 (en) HIV-1 gp41 FUSION PEPTIDES FOR IMMUNOMODULATION
WO2001045738A3 (en) Use of heat shock proteins to enhance production of chemokines by a cell
WO2007002172A3 (en) Hiv-1 protease inhibitors
WO2010041237A3 (en) Cyclic v3 peptides for anti hiv-1 vaccine
WO2006045616A3 (en) β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES
WO2002034909A3 (en) Engineered chimera of hiv protein fragments and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005706783

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3468/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580011458.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005706783

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0507949

Country of ref document: BR